FRX Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.…
Industry Peers
BiotechnologyKey Statistics
About Fennec Pharmaceuticals (TSE: FRX)
›
Fennec Pharmaceuticals (TSE: FRX) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 35 employees.
The shares were at 19.29 CAD on 19 November 2026, up 52.2% over 52 weeks. Its 52-week range is 7.590 CAD to 19.84 CAD: the price is 2.8% below the high and 154.2% above the low.
At a market capitalisation of 681.04M CAD, it trades at 482.3 times trailing earnings and 12.9 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a premium of 1339% for FRX.
Fennec Pharmaceuticals reports return on equity of -27.5%, an operating margin of 5.6% and revenue up 57.3% year over year.
It holds more cash than debt, a net cash position of 48.68M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 23 March 2027.